Innate Pharma (IPHA) EBITDA Margin (2019 - 2025)
Innate Pharma (IPHA) posted quarterly EBITDA Margin of 1876.46% for Q4 2025, down 145303.0% year-on-year from N/an in Q4 2024, and down 343.15% on a QoQ basis from 423.44% in Q4 2024.
Innate Pharma (IPHA) EBITDA Margin (2019 - 2025) Analysis & Trends
Innate Pharma (IPHA) has reported EBITDA Margin for 7 consecutive years, with 1876.46% the latest figure, recorded in Q4 2025.
- Quarterly EBITDA Margin fell 145303.0% year-over-year to 1876.46% in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 208.3% (down 12550.0% YoY) and the FY2025 annual result came in at 599.76%, down 34343.0% from the prior year.
- EBITDA Margin slipped to 1876.46% in Q4 2025 per IPHA's latest filing, from 423.44% in the prior quarter.
- Over the last five years, EBITDA Margin for IPHA reached as high as 0.03% in Q4 2022 and fell as low as 1876.46% in Q4 2025.
- A 5-year average of 433.05% and a median of 317.29% in 2024 frame the typical range for EBITDA Margin.
- Annual changes were most pronounced in 2022 — EBITDA Margin surged 39482 bps — and 2025, when it sank 145303 bps.
- Year by year, EBITDA Margin stood at 394.86% in 2021, then surged by 100 bps to 0.03% in 2022, then plunged by 54582 bps to 18.12% in 2023, then tumbled by 2237 bps to 423.44% in 2024, then plunged by 343 bps to 1876.46% in 2025.
- According to Business Quant data, EBITDA Margin over the past three periods registered 1876.46%, 423.44%, and 317.29% for Q4 2025, Q4 2024, and Q2 2024 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 16.51% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 38.10% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 17.83% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 31.68% |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Innate Pharma | 157.68 Mn | 157.68 Mn | - | -1,876.46% |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -1,876.46% |
| Dec 31, 2024 | -423.44% |
| Jun 30, 2024 | -317.29% |
| Dec 31, 2023 | -18.12% |
| Jun 30, 2023 | -1.13% |
| Dec 31, 2022 | -0.03% |
| Dec 31, 2021 | -394.86% |
| Dec 31, 2020 | -13.52% |
| Dec 31, 2019 | -37.31% |